Thromboxane B2

Thromboxane B2

SCHEMBL38223

CCCCC[C@H](O)/C=C/[C@H]1OC(O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 1.00
KMT2A Q03164 1/20 1.00
PTGFR P43088 4/20 0.74
TBXA2R P21731 6/20 0.73
ALDH1A1 P00352 5/20 0.73
LMNA P02545 4/20 0.73
PTGER4 P35408 4/20 0.73
PTGER1 P34995 3/20 0.73
PTGER3 P43115 3/20 0.73
SLCO2A1 Q92959 2/20 0.73
PTGDR Q13258 1/20 0.73
HPGD P15428 3/20 0.64
ABCC4 O15439 1/20 0.64
PTGDR2 Q9Y5Y4 1/20 0.63
TSHR P16473 2/20 0.60
MAPK1 P28482 2/20 0.60
HIF1A Q16665 1/20 0.60
PTGER2 P43116 3/20 0.58
PTGIR P43119 2/20 0.58
KDM4E B2RXH2 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thromboxane B2 SCHEMBL15263306 1.00 MEN1 (1.00) MEN1KMT2APTGFRTBXA2RALDH1A1
Thromboxane B2 SCHEMBL21820779 1.00 MEN1 (1.00) MEN1KMT2APTGFRTBXA2RALDH1A1
Thromboxane B2 SCHEMBL13179230 1.00 MEN1 (1.00) MEN1KMT2APTGFRTBXA2RALDH1A1
Thromboxane B2 SCHEMBL22972728 1.00 MEN1 (1.00) MEN1KMT2APTGFRTBXA2RALDH1A1
SCHEMBL31254102 0.92 MEN1 (0.84) MEN1KMT2APTGFRTBXA2RALDH1A1
SCHEMBL29559217 0.90 MEN1 (0.81) MEN1KMT2APTGFRTBXA2RALDH1A1
SCHEMBL3344355 0.90 MEN1 (0.81) MEN1KMT2APTGFRTBXA2RALDH1A1
SCHEMBL13179231 0.90 MEN1 (0.81) MEN1KMT2APTGFRTBXA2RALDH1A1
SCHEMBL38663703 0.90 MEN1 (0.81) MEN1KMT2APTGFRTBXA2RALDH1A1
Thromboxane B2 SCHEMBL9545161 0.89 MEN1 (0.79) MEN1KMT2APTGFRTBXA2RALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3819 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713459-A2 ANTI-VISTA ANTIBODY RNA OR NUCLEIC ACID CONJUGATES (ARCS OR ANCS), COMPOSITIONS CONTAINING, AND THERAPEUTIC USE THEREOF LIFORDI IMMUNOTHERAPEUTICS, INC. (US) 2026-03-25 EP claimed
US-20260038636-A1 METHODS OF TREATING CANCER FENG BIOSCIENCES, INC. (US) 2026-02-05 US claimed
EP-4678656-A1 METHODS FOR PRODUCING ATRIOVENTRICULAR CANAL (AVC)-LIKE CARDIOMYOCYTES Stichting Amsterdam UMC (NL) 2026-01-14 EP claimed
US-20250388862-A1 SYSTEMS FOR CELL PROGRAMMING AND METHODS THEREOF SYNTAX BIO INC (US) 2025-12-25 US claimed
EP-4658765-A2 SYSTEMS FOR CELL PROGRAMMING TOWARDS CHONDROGENIC LINEAGE AND METHODS THEREOF Syntax Bio, Inc. (US) 2025-12-10 EP claimed
EP-4658760-A2 SYSTEMS FOR CELL PROGRAMMING TOWARDS PANCREATIC LINEAGE AND METHODS THEREOF Syntax Bio, Inc. (US) 2025-12-10 EP claimed
US-20250340848-A1 METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS PEKING UNIVERSITY (CN) 2025-11-06 US claimed
WO-2025184468-A9 MEASUREMENT OF URINE THROMBOXANE METABOLITES TO PREDICT SURVIVAL UNIVERSITY OF MASSACHUSETTS (US) 2025-10-16 WO claimed
US-20250320458-A1 CARDIOMYOCYTE SUBTYPES AND METHODS OF MAKING AND USING UNIV HEALTH NETWORK (CA) 2025-10-16 US claimed
EP-4622648-A1 SELECTION OF PATIENTS FOR THE TREATMENT OF FADS1-MEDIATED DISEASES OR DISORDERS USING FADS-1 INHIBITORS Amgen Inc. (US) 2025-10-01 EP claimed
US-5427913-A Methods for determining platelet function ALBERTA CANCER BOARD (CA) 1995-06-27 US claimed
WO-1994012664-A1 METHODS FOR DETERMINING PLATELET FUNCTION ALBERTA CANCER BOARD (CA) 1994-06-09 WO claimed
EP-0166583-B1 COMPOSITIONS FOR ENZYME IMMUNOASSAY OF PROSTAGLANDINS ONO PHARMACEUTICAL CO., LTD. (JP) 1991-09-18 EP claimed
EP-0361817-A2 Nucleophilic polysubstituted aryl acridinium esters, conjugates, production and uses thereof Ciba Corning Diagnostics Corp. (US) 1990-04-04 EP claimed
EP-0310322-A2 Use of thromboxane B2 to constrict the pupil and lower intraocular pressure ALLERGAN, INC (US) 1989-04-05 EP claimed
EP-0139552-B1 COMPOUND LABELLED WITH ACETYLCHOLINE STERASE FROM ELECTROPHORUS ELECTRICUS, METHOD FOR ITS PREPARATION AND ITS USE AS A MARKER IN ENZYME IMMUNO ASSAYS COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 1989-02-08 EP claimed
EP-0223844-A1 COMPOUNDS AND METHODS USEFUL FOR THE SYNTHESIS OF THROMBOXANE A 2? THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 1987-06-03 EP claimed
WO-1986007058-A1 COMPOUNDS AND METHODS USEFUL FOR THE SYNTHESIS OF THROMBOXANE A2 THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF (US) 1986-12-04 WO claimed
EP-0166583-A2 Compositions for enzyme immunoassay of prostaglandins ONO PHARMACEUTICAL CO., LTD. (JP) 1986-01-02 EP claimed
EP-0139552-A1 Compound labelled with acetylcholine sterase from Electrophorus electricus, method for its preparation and its use as a marker in enzyme immuno assays COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 1985-05-02 EP claimed